Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective
- PMID: 28444890
- DOI: 10.1002/cpt.699
Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective
Abstract
Dasabuvir, a component of VIEKIRA PAK, is a substrate of CYP2C8 enzymes. Prescribing information for VIEKIRA PAK contraindicates gemfibrozil, a strong CYP2C8 inhibitor, because coadministration significantly increases dasabuvir exposures, which may increase the risk of QT prolongation. Clopidogrel may increase dasabuvir exposures primarily due to CYP2C8 inhibition by clopidogrel-acyl-β-D-glucuronide. This commentary outlines the US Food and Drug Administration (FDA) interdisciplinary review team's scientific perspective to address the potential for a significant drug-drug interaction (DDI) between clopidogrel and VIEKIRA PAK.
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Similar articles
-
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Clin Pharmacol Ther. 2017 Oct;102(4):679-687. doi: 10.1002/cpt.689. Epub 2017 Jun 3. Clin Pharmacol Ther. 2017. PMID: 28411400 Free PMC article.
-
Clinical Pharmacokinetics of Dasabuvir.Clin Pharmacokinet. 2017 Oct;56(10):1115-1124. doi: 10.1007/s40262-017-0519-3. Clin Pharmacokinet. 2017. PMID: 28258380 Review.
-
Potential for a Significant Interaction Between Clopidogrel and Dasabuvir.Clin Infect Dis. 2015 Jul 1;61(1):134-5. doi: 10.1093/cid/civ246. Epub 2015 Mar 25. Clin Infect Dis. 2015. PMID: 25810285 No abstract available.
-
A 4-drug combination (Viekira Pak) for hepatitis C.Med Lett Drugs Ther. 2015 Feb 2;57(1461):15-7. Med Lett Drugs Ther. 2015. PMID: 25629810 Review. No abstract available.
-
A 4-drug combination (Viekira Pak) for hepatitis C.JAMA. 2015 May 12;313(18):1857-8. doi: 10.1001/jama.2015.4562. JAMA. 2015. PMID: 25965236 No abstract available.
Cited by
-
Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.Clin Pharmacokinet. 2019 Nov;58(11):1355-1371. doi: 10.1007/s40262-019-00790-0. Clin Pharmacokinet. 2019. PMID: 31236775 Free PMC article.
-
Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel.Clin Pharmacol Ther. 2019 Jan;105(1):219-228. doi: 10.1002/cpt.1099. Epub 2018 Aug 9. Clin Pharmacol Ther. 2019. PMID: 29696643 Free PMC article. Clinical Trial.
-
Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.Curr Pharmacol Rep. 2020;6(3):71-84. doi: 10.1007/s40495-020-00212-x. Epub 2020 May 12. Curr Pharmacol Rep. 2020. PMID: 32399388 Free PMC article. Review.
-
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Clin Pharmacol Ther. 2018. PMID: 29315504 Free PMC article. Review.
-
Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.Clin Pharmacokinet. 2020 May;59(5):617-627. doi: 10.1007/s40262-019-00833-6. Clin Pharmacokinet. 2020. PMID: 31713224 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
